Trending News Today: Leukemia Drug May Also Treat Alzheimer's, Parkinson's Disease

Clover Health is involved in a deal to raise approximately $120 million in new capital at a valuation of more than $1 billion, according to The Wall Street Journal. The health insurance startup is seeking to become “the largest health care company in the United States.” Currently, the NJ-based company provides Medicare Advantage plans to seniors across the state.
 
Investigators are hopeful that an FDA-approved cancer drug that treats a rare form of leukemia could be used to treat Parkinson’s disease and Alzheimer’s disease. In late 2015, investigators found that small doses of nilotinib appeared to help individuals with Parkinson’s and Alzheimer’s disease, according to NPR. The preliminary study sparked excitement among the research community because there are currently no treatments available for these diseases. However, some scientists are cautious because the trial was small, lacked a placebo control, and was not designed to assess efficacy. As a result, investigators are launching 2 larger and more rigorous trials of nilotinib that are both designed with input from the FDA, reported NPR. One clinical trial will include 75 patients with Parkinson’s disease, while the other will contain 42 patients with Alzheimer’s disease. The primary goal of the studies is to determine if the cancer drug is safe in patients with brain disease. But the studies should also provide more evidence on whether the drug truly works.
 
After the Ebola and Zika virus epidemics caused worldwide panic, health officials have advocated for a special emergency fund that would allow the United States to respond quickly to disease outbreaks. Now, a budget blueprint for Federal Emergency Response Funds has been proposed to address public health outbreaks. However, it provides no specifics about how large it would be or where the funds will come from, according to The Washington Post.
 


Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 


Related Articles

Researchers seek to investigate how to broaden the potential of cediranib with and olaparib to treat multiple cancer types.
Among the most prevalent symptoms of chimeric antigen receptor T-cell therapy is encephalopathy.
Study suggests a possible co-treatment strategy to overcome resistance to Venetoclax in the treatment of chronic lymphocyte leukemia and acute myeloid leukemia.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$